Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 228

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 16G
Chunk 228
---
ITEM 16G. CORPORATE GOVERNANCE

As a foreign private issuer, we are permitted,
and intend, to follow certain home country corporate governance practices instead of those otherwise required by the Nasdaq for domestic
U. S. issuers. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U. S. company
listed on The Nasdaq Global Market may provide less protection to you than what is accorded to investors under the Nasdaq Rules applicable
to domestic U. S. issuers.

Accordingly, we have elected to follow the provisions,
rather than the Nasdaq Rules, with respect to the following requirements:

  Distribution of periodic reports to shareholders;                                                                                       
  Quorum. While the Nasdaq Rules require that                                                                                             

  Nomination of our directors. Our amended                                                                                                  

  Compensation of officers. Israeli law and                                                                                                 
  our amended and restated articles of association does not require that the independent members of our Board (or a Compensation Committee  
  composed solely of independent members of our Board) determine an executive officer’s compensation, as is generally required              
  under the Nasdaq Rules with respect to the chief executive officer and all other executive officers. Instead, compensation of executive   
  officers is determined and approved by our Compensation Committee and our Board, and in certain circumstances by our shareholders,        
  either in consistency with our office holder compensation policy or, in special circumstances in deviation therefrom, taking into         
  account certain considerations stated in the Companies Law.                                                                               
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Independent directors. Israeli law does                                                                                                    
  Shareholder approval. We will seek shareholder                                                                                             

  Approval of Related Party Transactions. All                                                                                            
  related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts       
  and transaction as set forth in the Companies Law, which requires the approval of the Audit Committee, or the Compensation Committee,  
  as the case may be, the Board and shareholders, as may be applicable, for specified transactions, rather than approval by the Audit    
  Committee or other independent body of our Board as required under the Nasdaq Rules.                                                   
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

ITEM 16H. MINE SAFETY DISCLOSURE